Your browser doesn't support javascript.
loading
Donated chemical probes for open science.
Müller, Susanne; Ackloo, Suzanne; Arrowsmith, Cheryl H; Bauser, Marcus; Baryza, Jeremy L; Blagg, Julian; Böttcher, Jark; Bountra, Chas; Brown, Peter J; Bunnage, Mark E; Carter, Adrian J; Damerell, David; Dötsch, Volker; Drewry, David H; Edwards, Aled M; Edwards, James; Elkins, Jon M; Fischer, Christian; Frye, Stephen V; Gollner, Andreas; Grimshaw, Charles E; IJzerman, Adriaan; Hanke, Thomas; Hartung, Ingo V; Hitchcock, Steve; Howe, Trevor; Hughes, Terry V; Laufer, Stefan; Li, Volkhart Mj; Liras, Spiros; Marsden, Brian D; Matsui, Hisanori; Mathias, John; O'Hagan, Ronan C; Owen, Dafydd R; Pande, Vineet; Rauh, Daniel; Rosenberg, Saul H; Roth, Bryan L; Schneider, Natalie S; Scholten, Cora; Singh Saikatendu, Kumar; Simeonov, Anton; Takizawa, Masayuki; Tse, Chris; Thompson, Paul R; Treiber, Daniel K; Viana, Amélia Yi; Wells, Carrow I; Willson, Timothy M.
Afiliação
  • Müller S; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Ackloo S; Structural Genomics Consortium, University of Toronto, Toronto, Canada.
  • Arrowsmith CH; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
  • Bauser M; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany.
  • Baryza JL; Vertex Pharmaceuticals, Boston, United States.
  • Blagg J; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Böttcher J; Discovery Research, Boehringer Ingelheim, Vienna, Austria.
  • Bountra C; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Brown PJ; Structural Genomics Consortium, University of Toronto, Toronto, Canada.
  • Bunnage ME; Vertex Pharmaceuticals, Boston, United States.
  • Carter AJ; Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany.
  • Damerell D; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Dötsch V; Institute of Biophysical Chemistry, Goethe-University, Frankfurt am Main, Germany.
  • Drewry DH; Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt am Main, Germany.
  • Edwards AM; Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States.
  • Edwards J; Structural Genomics Consortium, University of Toronto, Toronto, Canada.
  • Elkins JM; Janssen Pharmaceutical Research and Development LLC, Spring House, United States.
  • Fischer C; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Frye SV; Merck & Co., Inc., Boston, United States.
  • Gollner A; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States.
  • Grimshaw CE; Discovery Research, Boehringer Ingelheim, Biberach an der Riss, Germany.
  • IJzerman A; Ched Grimshaw Consulting, LLC, Poway, United States.
  • Hanke T; Division of Medicinal Chemistry, Leiden University, Leiden, Netherlands.
  • Hartung IV; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Hitchcock S; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany.
  • Howe T; Takeda California Inc., San Diego, United States.
  • Hughes TV; J&J Innovation Centre, London, United Kingdom.
  • Laufer S; J&J Innovation Centre, London, United Kingdom.
  • Li VM; Department of Pharmaceutical Chemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.
  • Liras S; Drug Discovery Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  • Marsden BD; Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States.
  • Matsui H; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Mathias J; Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
  • O'Hagan RC; Takeda Pharmaceutical Company Ltd, Fujisawa, Japan.
  • Owen DR; Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States.
  • Pande V; Merck & Co., Inc., Boston, United States.
  • Rauh D; Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States.
  • Rosenberg SH; Discovery Sciences, Janssen-Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium.
  • Roth BL; Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, Germany.
  • Schneider NS; AbbVie, North Chicago, United States.
  • Scholten C; The National Institute of Mental Health Psychoactive Active Drug Screening Program, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, United States.
  • Singh Saikatendu K; Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Simeonov A; Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany.
  • Takizawa M; Takeda California Inc., San Diego, United States.
  • Tse C; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, United States.
  • Thompson PR; Takeda Pharmaceutical Company Ltd., Fujisawa, Japan.
  • Treiber DK; AbbVie, North Chicago, United States.
  • Viana AY; Department of Biochemistry and Pharmacology, University of Massachusetts Medical School, Worcester, United States.
  • Wells CI; Eurofins DiscoverX, Sane Diego, United States.
  • Willson TM; Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany.
Elife ; 72018 04 20.
Article em En | MEDLINE | ID: mdl-29676732
ABSTRACT
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and control compounds, such as inactive structurally related molecules and their associated data, are generally not accessible. The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose. Several pharmaceutical companies (AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Takeda) have therefore entered into a pre-competitive collaboration to make available a large number of innovative high-quality probes, including all probe-associated data, control compounds and recommendations on use (https//openscienceprobes.sgc-frankfurt.de/). Here we describe the chemical tools and target-related knowledge that have been made available, and encourage others to join the project.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacologia / Sondas Moleculares / Proteínas / Tecnologia Farmacêutica Idioma: En Revista: Elife Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacologia / Sondas Moleculares / Proteínas / Tecnologia Farmacêutica Idioma: En Revista: Elife Ano de publicação: 2018 Tipo de documento: Article